Monday, 29 September 2014

Hundreds of firms join global hunt for copycat biotech drugs

By Ben Hirschler (Reuters) - Hundreds of companies around the world are chasing an emerging market for cheaper copies of costly biotech drugs, with more than 700 so-called biosimilars now in development or already approved, according to a major study of the sector. Biotech medicines - made from proteins and other large molecules - account for six of the 10 biggest-selling drugs in the world today, led by AbbVie's $12 billion-a-year rheumatoid arthritis injection Humira. ... via Health News Headlines - Yahoo News Read More Here..


Lake forest health and fitness http://ift.tt/1DQEgKN

No comments:

Post a Comment